| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Generates an Autocrine Tumor-Promoting Network in Epithelial Ovarian Cancer Cells
1 Centre for Translational Oncology, Institute of Cancer and the Cancer Research-UK Clinical Centre and 2 Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom and 3 Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey
Requests for reprints: Frances Balkwill, Biological Therapy Laboratory, Imperial Cancer Research Fund, P.O. Box 123, London WC2A 3PX, United Kingdom. Phone: 44-207-882-6106; E-mail: frances.balkwill{at}cancer.org.uk.
Constitutive expression of the inflammatory cytokine tumor necrosis factor-
(TNF-) is characteristic of malignant ovarian surface epithelium. We investigated the hypothesis that this autocrine action of TNF- generates and sustains a network of other mediators that promote peritoneal cancer growth and spread. When compared with two ovarian cancer cell lines that did not make TNF-, constitutive production of TNF- was associated with greater release of the chemokines CCL2 and CXCL12, the cytokines interleukin-6 (IL-6) and macrophage migration-inhibitory factor (MIF), and the angiogenic factor vascular endothelial growth factor (VEGF). TNF- production was associated also with increased peritoneal dissemination when the ovarian cancer cells were xenografted. We next used RNA interference to generate stable knockdown of TNF- in ovarian cancer cells. Production of CCL2, CXCL12, VEGF, IL-6, and MIF was decreased significantly in these cells compared with wild-type or mock-transfected cells, but in vitro growth rates were unaltered. Tumor growth and dissemination in vivo were significantly reduced when stable knockdown of TNF- was achieved. Tumors derived from TNF- knockdown cells were noninvasive and well circumscribed and showed high levels of apoptosis, even in the smallest deposits. This was reflected in reduced vascularization of TNF- knockdown tumors. Furthermore, culture supernatants from such cells failed to stimulate endothelial cell growth in vitro. We conclude that autocrine production of TNF- by ovarian cancer cells stimulates a constitutive network of other cytokines, angiogenic factors, and chemokines that may act in an autocrine/paracrine manner to promote colonization of the peritoneum and neovascularization of developing tumor deposits. [Cancer Res 2007;67(2):585–92]
This article has been cited by other articles:
|
|
 |
|
  R. C.M. van Kruijsdijk, E. van der Wall, and F. L.J. Visseren Obesity and Cancer: The Role of Dysfunctional Adipose Tissue Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Warren, S. F. Shoemaker, D. J. Shealy, W. Bshar, and M. M. Ip Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice Mol. Cancer Ther., September 1, 2009; 8(9): 2655 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Carcinogenesis, July 1, 2009; 30(7): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xiao, C. Wang, J. Zhang, Z. Li, X. Zhao, and Z. Qin IFN{gamma} Promotes Papilloma Development by Up-regulating Th17-Associated Inflammation Cancer Res., March 1, 2009; 69(5): 2010 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, A. Vincent, J. Cates, D. M. Brantley-Sieders, D. B. Polk, and P. P. Young Low Levels of Tumor Necrosis Factor {alpha} Increase Tumor Growth by Inducing an Endothelial Phenotype of Monocytes Recruited to the Tumor Site Cancer Res., January 1, 2009; 69(1): 338 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mantovani Cancer-related Inflammation: The Seventh Hallmark of Cancer ASCO Educational Book, January 1, 2009; 2009(1): 723 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marchini, P. Mariani, G. Chiorino, E. Marrazzo, R. Bonomi, R. Fruscio, L. Clivio, A. Garbi, V. Torri, M. Cinquini, et al. Analysis of Gene Expression in Early-Stage Ovarian Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7850 - 7860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Stathopoulos, I. Psallidas, A. Moustaki, C. Moschos, A. Kollintza, S. Karabela, I. Porfyridis, S. Vassiliou, M. Karatza, Z. Zhou, et al. A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion J Natl Cancer Inst, October 15, 2008; 100(20): 1464 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Huang, Z. Lei, G.-M. Zhang, D. Li, C. Song, B. Li, Y. Liu, Y. Yuan, J. Unkeless, H. Xiong, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment Blood, August 15, 2008; 112(4): 1269 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Brown, K. A. Charles, S. A. Hoare, R. L. Rye, D. I. Jodrell, R. E. Aird, R. Vora, U. Prabhakar, M. Nakada, R. E. Corringham, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer Ann. Onc., July 1, 2008; 19(7): 1340 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hagemann, T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill "Re-educating" tumor-associated macrophages by targeting NF-{kappa}B J. Exp. Med., June 9, 2008; 205(6): 1261 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Egberts, V. Cloosters, A. Noack, B. Schniewind, L. Thon, S. Klose, B. Kettler, C. von Forstner, C. Kneitz, J. Tepel, et al. Anti-Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., March 1, 2008; 68(5): 1443 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Stathopoulos, A. Kollintza, C. Moschos, I. Psallidas, T. P. Sherrill, E. N. Pitsinos, S. Vassiliou, M. Karatza, S. A. Papiris, D. Graf, et al. Tumor Necrosis Factor-{alpha} Promotes Malignant Pleural Effusion Cancer Res., October 15, 2007; 67(20): 9825 - 9834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Harrison, E. Obermueller, N. R. Maisey, S. Hoare, K. Edmonds, N. F. Li, D. Chao, K. Hall, C. Lee, E. Timotheadou, et al. Tumor Necrosis Factor {alpha} As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose J. Clin. Oncol., October 10, 2007; 25(29): 4542 - 4549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hagemann, S. C. Robinson, R. G. Thompson, K. Charles, H. Kulbe, and F. R. Balkwill Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis Mol. Cancer Ther., July 1, 2007; 6(7): 1993 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice Cancer Res., June 15, 2007; 67(12): 5708 - 5716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Balkwill Inflammation and Cancer: the TNF-{alpha} Connection Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 39 - 42. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
